EUVIMEDEUVIMED entdecken
Crossref

Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform

William B Feldman iD

Journal of Law, Medicine & Ethics · 2025 · 53 (1) · 158-163

DOI: 10.1017/jme.2025.54 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Law, Medicine & Ethics, online erschienen am 08.04.2025. Verfasst von William B Feldman. Beteiligte Einrichtung: Brigham and Women's Hospital and Harvard Medical School. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Commonwealth Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Two key strategies that brand-name pharmaceutical manufacturers employ to limit generic competition are patent thickets and product hops. The former strategy entails obtaining numerous patents on peripheral features of products (not just the active ingredients), and the latter involves shifting active ingredients into reformulations with new patent protection that can extend periods of market exclusivity. These strategies have become particularly problematic for drug-device combinations like inhalers and glucagon-like peptide-1 receptor agonists, which contain pharmaceutical compounds that are sold together with their delivery devices. The Senate Judiciary Committee moved three bipartisan bills out of committee during the last legislative session aimed at facilitating more timely generic competition. Although these bills offer a valuable step forward, more is needed to limit the sort of patent gamesmanship that has become pervasive in the US pharmaceutical industry. Such reforms should include routine reexamination by the US Patent and Trademark Office of patents submitted for listing with the Food and Drug Administration (FDA), a greater role for the FDA in reviewing such listings, limits on the number of patents that brand-name firms can assert when suing for infringement following patent challenges, stronger incentives for patent challenges, and more flexibility for the FDA to approve complex generic drugs.

Schlagwörter

Stichwörter der Autor:innen

Food and Drug AdministrationGLP-1 receptor agonistinhalerpatent thicketsproduct hops

Autor:innen und Institutionen

  • Brigham and Women's Hospital and Harvard Medical School.

ORCID-Profile: William B Feldman

Förderung

  • Commonwealth Fund

Zitieren

APA

Feldman, W. B. (2025). Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform. Journal of Law, Medicine & Ethics, 53(1), 158-163. https://doi.org/10.1017/jme.2025.54

Vancouver

Feldman WB. Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform. Journal of Law, Medicine & Ethics. 2025;53(1):158-163. doi:10.1017/jme.2025.54

BibTeX
@article{Feldman2025,
  author = {Feldman, William B},
  title = {Patent Thickets and Product Hops: Challenges and Opportunities for Legislative Reform},
  journal = {Journal of Law, Medicine & Ethics},
  year = {2025},
  volume = {53},
  number = {1},
  pages = {158--163},
  doi = {10.1017/jme.2025.54}
}
Kostenlos starten →